tag:blogger.com,1999:blog-8170933399396423373.post3085241516527558357..comments2024-02-27T19:00:38.803+05:30Comments on Hyd&Spook: Compulsory Licensing, Nexavar, Natco Pharma issueHyd&Spookhttp://www.blogger.com/profile/18061172446704649416noreply@blogger.comBlogger1125tag:blogger.com,1999:blog-8170933399396423373.post-35324242136538810202012-10-02T14:30:00.647+05:302012-10-02T14:30:00.647+05:30One more related issue is the Novartis' drug G...One more related issue is the Novartis' drug Glivec. The patent was rejected by the Indian Patent office as the drug does not classify under the "enhanced efficacy" conditionality of the article 3(d) of the Indian Patent Act.Anonymoushttps://www.blogger.com/profile/13908393178807465469noreply@blogger.com